Prothena Corporation Plc (PRTA) 66.35 $PRTA 3 Long Shots

New Post Public Reply Private Reply Replies (0) Message Board

Jul 29, 2015 at 1:44 PM

Prothena Corporation Plc (PRTA) 66.35 $PRTA

3 Long Shots Biotech Companies Are Working On
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 10, 4:04PM CDT
Source: Flickr user Micolo J. The Holy Grail of biotech companies is a billion-dollar blockbuster therapy, but more often than not, efforts to invent game-changing medicines that can eclipse the billion-dollar threshold fall short. That's...
BIIB: 311.57 (-8.36), PRTA: 66.35 (-2.35)

Why Shares of Prothena Surged 33% Higher in June
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 04, 10:02AM CDT
Source: Prothena Corp. Plc Compelling early stage trial data for Prothena Corp. Plc 's PRX002 as a therapy for Parkinson's disease sent the company's shares soaring 33.5% in June. Offering new hope Prothena is developing PRX002 with ...
PRTA: 66.35 (-2.35)

10 Best Biotech Stocks in the NASDAQ
at The Street - Wed Jul 01, 10:23AM CDT
The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.
SGYP: 8.13 (-0.11), HALO: 23.25 (-0.46), RARE: 117.45 (-3.15), KYTH: 74.49 (-0.03), RTRX: 31.70 (-1.33), IMGN: 17.62 (-0.48), HZNP: 36.68 (-1.64), ANAC: 147.93 (-3.38), PRTA: 66.35 (-2.35), EXEL: 5.66 (+0.25)

Prothena Announces Addition of Seasoned Executive to Board of Directors
Thomson Reuters ONE - Mon Jun 29, 3:05PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
PRTA: 66.35 (-2.35)

5 Stocks Leading XBI Biotech ETF Higher
Zacks Funds - Seeking Alpha - Fri Jun 26, 5:09AM CDT
The biotech corner of the health care space is having a stellar run like last year and still remains a favorite investment destination for investors. This is primarily thanks to strong earnings growth, merger & acquisition frenzy, promising drug...
HRTX: 32.73 (-1.16), XBI: 252.10 (-6.84), RTRX: 31.70 (-1.33), EGRX: 92.18 (-0.66), PRTA: 66.35 (-2.35), EXEL: 5.66 (+0.25)

5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Jun 25, 9:30AM CDT
These five stocks have contributed much to the outstanding performance of this biotech ETF.
HRTX: 32.73 (-1.16), XBI: 252.10 (-6.84), RTRX: 31.70 (-1.33), EGRX: 92.18 (-0.66), PRTA: 66.35 (-2.35), EXEL: 5.66 (+0.25)

Seeking Alpha's Biotech Weekly: Bubble Trouble, Allergan's Kythera Takeout, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jun 19, 3:08PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGN: 337.97 (-1.53), ACAD: 48.14 (-1.16), KYTH: 74.49 (-0.03), TKMR: 10.27 (unch), AMGN: 169.91 (-2.83), AERI: 18.46 (-0.68), TEVA: 71.05 (-0.36), LLY: 85.06 (-0.62), PRTA: 66.35 (-2.35), NVS: 103.78 (+0.99), HCC: 77.18 (-0.07)

The Makings Of A Biotech Bubble
Bret Jensen - at Seeking Alpha - Wed Jun 17, 12:06PM CDT

AGEN: 8.17 (-0.16), CRIS: 3.13 (-0.04), TTPH: 46.89 (-1.46), XBI: 252.10 (-6.84), IBB: 376.44 (-6.40), ABBV: 71.38 (+0.15), EGRX: 92.18 (-0.66), PRTA: 66.35 (-2.35), CELG: 132.90 (-2.52)

Prothena's PRX002 knocks down PD-related protein 96% in early stage study
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 7:15AM CDT

PRTA: 66.35 (-2.35)

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002...
Thomson Reuters ONE - Wed Jun 17, 6:00AM CDT
- PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
PRTA: 66.35 (-2.35)

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease
GlobeNewswire - Wed Jun 17, 6:00AM CDT
-- PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
PRTA: 66.35 (-2.35)

Prothena to Present at JMP Securities Life Science Conference 2015 on June 23
Thomson Reuters ONE - Tue Jun 16, 3:06PM CDT
DUBLIN, Ireland, June 16, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that members of the senior management team will present and participate in investor meetings at the JMP Securities Life Science Conference 2015 on June 23 at 10 a.m. EDT at The St. Regis in New York, NY.
PRTA: 66.35 (-2.35)

Prothena's NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association
Thomson Reuters ONE - Fri Jun 12, 6:05AM CDT
DUBLIN, Ireland, June 12, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq

RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dr. Michaela Liedtke of Stanford University School of Medicine presented data from the ongoing Phase 1/2 trial of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction in an oral presentation (Abstract #S104) during the 20th Congress of the European Hematology Association (EHA) in Vienna.
PRTA: 66.35 (-2.35)

Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association
Thomson Reuters ONE - Fri Jun 12, 6:00AM CDT
- 72% of Survey Respondents had AL Amyloidosis
PRTA: 66.35 (-2.35)

Prothena (PRTA) Starts Phase I Study on Psoriasis Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 10, 2:35PM CDT
Prothena Corporation plc (PRTA) dosed the first patient in a phase I study on PRX003 for the potential treatment of psoriasis and other inflammatory diseases.
VRX: 254.49 (-3.46), PRTA: 66.35 (-2.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

CVS Study: GLP-1 Drugs Effective But Costly

By Hannah Lewis Updated Nov 15, 2026 Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

IDEAYA's IDE101: A New Front in Cancer Battle

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Employment Law Suit Hits ABC: Alleged Wage Violations

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Berry Street Integrates AI with What Matters: Human Touch

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Investors Gear Up for Lennar Class Action Lawsuit

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...